CoChat

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

Open access

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND: NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles. We conducted an open-label phase III non-inferiority trial to compare the efficacy and safety of NK105 and PTX in metastatic or recurrent breast cancer. METHODS: ) on days 1, 8 and 15 of a 28-day cycle. The primary endpoint was progression-free survival (PFS), with a non-inferiority margin of 1.215. RESULTS: A total of 436 patients were randomised and 211 patients in each group were included in the efficacy analysis. The median PFS was 8.4 and 8.5 months for NK105 and PTX, respectively (adjusted hazard ratio: 1.255; 95% confidence interval: 0.989-1.592). The median overall survival and overall response rates were 31.2 vs. 36.2 months and 31.6% vs. 39.0%, respectively. The two groups exhibited similar safety profiles. The incidence of peripheral sensory neuropathy (PSN) was 1.4% vs. 7.5% (≥Grade 3) for NK105 and PTX, respectively. The patient-reported outcomes of PSN were significantly favourable for NK105 (P < 0.0001). CONCLUSIONS: The primary endpoint was not met, but NK105 had a better PSN toxicity profile than PTX. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT01644890.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-019-0391-z

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Kaplan–Meier curves for progression-free survival in full analysis set
Fig. 1 Kaplan–Meier curves for progression-free survival in full analysis setCC BY · PubMed Central
Fig. 2 Kaplan–Meier curves for overall survival in full analysis set
Fig. 2 Kaplan–Meier curves for overall survival in full analysis setCC BY · PubMed Central
Fig. 3 Cumulative incidence of peripheral sensory neuropathy
Fig. 3 Cumulative incidence of peripheral sensory neuropathyCC BY · PubMed Central
Fig. 4 Patient-reported outcomes of peripheral sensory neuropathy assessed by FACT/GOG-NTX subscale
Fig. 4 Patient-reported outcomes of peripheral sensory neuropathy assessed by FACT/GOG-NTX subscaleCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 147

Metadata

Authors
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., Kuroi, K., Tsugawa, K., Tokuda, Y., Iwata, H., Park, Y. H., Yang, Y., & Nambu, Y.
Affiliations
  • National Cancer Center Hospital (JP)
  • National Cancer Center Hospital East (JP)
  • Saitama International Medical Center (JP)
  • National Cancer Center (KR)
  • Chang Gung Memorial Hospital (TW)
  • Saitama Cancer Center (JP)
  • Shizuoka Cancer Center (JP)
  • Hiroshima City Hiroshima Citizens Hospital (JP)
  • Asan Medical Center (KR)
  • Tokyo Metropolitan Komagome Hospital (JP)
  • St. Marianna University School of Medicine (JP)
  • Tokai University (JP)
  • Aichi Cancer Center (JP)
  • Samsung Medical Center (KR)
  • China Medical University (TW)
  • Nippon Kayaku (Japan) (JP)
Corresponding author
Mukai, Hirofumi
Venue
British Journal of Cancer
Published
2019-02-12
Volume
120
Issue
5
Pages
475-480
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2912831482
Cited by
147
References
18
Citations by year
2026: 25 · 2025: 16 · 2024: 15 · 2023: 22 · 2022: 20 · 2021: 21 · 2020: 20 · 2019: 8
FWCI
7.21
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
paclitaxel, metastatic breast cancer, breast cancer recurrence, polymeric micelles, nanoparticle drug delivery, non-inferiority, progression-free survival, peripheral sensory neuropathy, patient-reported outcomes, chemotherapy toxicity
MeSH terms
Equivalence Trials as Topic, Progression-Free Survival, Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Peripheral Nervous System Diseases, Proportional Hazards Models, Paclitaxel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. https://app.cochat.ai/papers/10.1038/s41416-019-0391-z
The paper
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., Kuroi, K., Tsugawa, K., Tokuda, Y., Iwata, H., Park, Y. H., Yang, Y., & Nambu, Y. (2019). A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0391-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.